Impact of long-term white matter hyperintensity changes on mobility and dexterity.

dexterity imaging mobility small vessel disease white matter hyperintensity

Journal

Brain communications
ISSN: 2632-1297
Titre abrégé: Brain Commun
Pays: England
ID NLM: 101755125

Informations de publication

Date de publication:
2024
Historique:
received: 26 10 2023
revised: 26 01 2024
accepted: 24 04 2024
medline: 8 5 2024
pubmed: 8 5 2024
entrez: 8 5 2024
Statut: epublish

Résumé

White matter hyperintensities (WMH), a common feature of cerebral small vessel disease, are related to worse clinical outcomes after stroke. We assessed the impact of white matter hyperintensity changes over 1 year after minor stroke on change in mobility and dexterity, including differences between the dominant and non-dominant hands and objective in-person assessment versus patient-reported experience. We recruited participants with lacunar or minor cortical ischaemic stroke, performed medical and cognitive assessments and brain MRI at presentation and at 1 year. At both time points, we used the timed-up and go test and the 9-hole peg test to assess mobility and dexterity. At 1 year, participants completed the Stroke Impact Scale. We ran two linear mixed models to assess change in timed-up and go and 9-hole peg test, adjusted for age, sex, stroke severity (National Institutes of Health Stroke Scale), dependency (modified Rankin Score), vascular risk factor score, white matter hyperintensity volume (as % intracranial volume) and additionally for 9-hole peg test: Montreal cognitive assessment, hand (dominant/non-dominant), National Adult Reading Test (premorbid IQ), index lesion side. We performed ordinal logistic regression, corrected for age and sex, to assess relations between timed-up and go and Stroke Impact Scale mobility, and 9-hole peg test and Stroke Impact Scale hand function. We included 229 participants, mean age 65.9 (standard deviation = 11.13); 66% male. 215/229 attended 1-year follow-up. Over 1 year, timed-up and go time increased with aging (standardized β [standardized 95% Confidence Interval]: 0.124[0.011, 0.238]), increasing National Institutes of Health Stroke Scale (0.106[0.032, 0.180]), increasing modified Rankin Score (0.152[0.073, 0.231]) and increasing white matter hyperintensity volume (0.176[0.061, 0.291]). Men were faster than women (-0.306[0.011, 0.238]). Over 1 year, slower 9-hole peg test was related to use of non-dominant hand (0.290[0.155, 0.424]), aging (0.102[0.012, 0.192]), male sex (0.182[0.008, 0.356]), increasing National Institutes of Health Stroke Scale (0.160 [0.094, 0.226]), increasing modified Rankin Score (0.100[0.032, 0.169]), decreasing Montreal cognitive assessment score (-0.090[-0.167, -0.014]) and increasing white matter hyperintensity volume (0.104[0.015, 0.193]). One year post-stroke, Stroke Impact Scale mobility worsened per second increase on timed-up and go, odds ratio 0.67 [95% confidence interval 0.60, 0.75]. Stroke Impact Scale hand function worsened per second increase on the 9-hole peg test for the dominant hand (odds ratio 0.79 [0.71, 0.86]) and for the non-dominant hand (odds ratio 0.88 [0.83, 0.93]). Decline in mobility and dexterity is associated with white matter hyperintensity volume increase, independently of stroke severity. Mobility and dexterity declined more gradually for stable and regressing white matter hyperintensity volume. Dominant and non-dominant hands might be affected differently. In-person measures of dexterity and mobility are associated with self-reported experience 1-year post-stroke.

Identifiants

pubmed: 38715716
doi: 10.1093/braincomms/fcae133
pii: fcae133
pmc: PMC11074793
doi:

Types de publication

Journal Article

Langues

eng

Pagination

fcae133

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of the Guarantors of Brain.

Déclaration de conflit d'intérêts

The authors report no competing interests.

Auteurs

Angela C C Jochems (ACC)

Centre for Clinical Brain Sciences, University of Edinburgh, EH16 4SB Edinburgh, United Kingdom.
MRC UK Dementia Research Institute at the University of Edinburgh, EH16 4SB Edinburgh, United Kingdom.

Susana Muñoz Maniega (S)

Centre for Clinical Brain Sciences, University of Edinburgh, EH16 4SB Edinburgh, United Kingdom.
MRC UK Dementia Research Institute at the University of Edinburgh, EH16 4SB Edinburgh, United Kingdom.

Francesca M Chappell (FM)

Centre for Clinical Brain Sciences, University of Edinburgh, EH16 4SB Edinburgh, United Kingdom.
MRC UK Dementia Research Institute at the University of Edinburgh, EH16 4SB Edinburgh, United Kingdom.

Una Clancy (U)

Centre for Clinical Brain Sciences, University of Edinburgh, EH16 4SB Edinburgh, United Kingdom.
MRC UK Dementia Research Institute at the University of Edinburgh, EH16 4SB Edinburgh, United Kingdom.

Carmen Arteaga (C)

Centre for Clinical Brain Sciences, University of Edinburgh, EH16 4SB Edinburgh, United Kingdom.
MRC UK Dementia Research Institute at the University of Edinburgh, EH16 4SB Edinburgh, United Kingdom.

Daniela Jaime Garcia (D)

Centre for Clinical Brain Sciences, University of Edinburgh, EH16 4SB Edinburgh, United Kingdom.
MRC UK Dementia Research Institute at the University of Edinburgh, EH16 4SB Edinburgh, United Kingdom.

Olivia K L Hamilton (OKL)

Centre for Clinical Brain Sciences, University of Edinburgh, EH16 4SB Edinburgh, United Kingdom.
MRC UK Dementia Research Institute at the University of Edinburgh, EH16 4SB Edinburgh, United Kingdom.
MRC/CSO Social and Public Health Sciences Unit, School of Health and Wellbeing, University of Glasgow, G12 8TB Glasgow, United Kingdom.

Will Hewins (W)

Centre for Clinical Brain Sciences, University of Edinburgh, EH16 4SB Edinburgh, United Kingdom.
MRC UK Dementia Research Institute at the University of Edinburgh, EH16 4SB Edinburgh, United Kingdom.

Rachel Locherty (R)

Centre for Clinical Brain Sciences, University of Edinburgh, EH16 4SB Edinburgh, United Kingdom.
MRC UK Dementia Research Institute at the University of Edinburgh, EH16 4SB Edinburgh, United Kingdom.

Ellen V Backhouse (EV)

Centre for Clinical Brain Sciences, University of Edinburgh, EH16 4SB Edinburgh, United Kingdom.
MRC UK Dementia Research Institute at the University of Edinburgh, EH16 4SB Edinburgh, United Kingdom.

Gayle Barclay (G)

Centre for Clinical Brain Sciences, University of Edinburgh, EH16 4SB Edinburgh, United Kingdom.
Edinburgh Imaging Facility, Royal Infirmary of Edinburgh, EH16 4TJ Edinburgh, United Kingdom.

Charlotte Jardine (C)

Centre for Clinical Brain Sciences, University of Edinburgh, EH16 4SB Edinburgh, United Kingdom.
Edinburgh Imaging Facility, Royal Infirmary of Edinburgh, EH16 4TJ Edinburgh, United Kingdom.

Donna McIntyre (D)

Centre for Clinical Brain Sciences, University of Edinburgh, EH16 4SB Edinburgh, United Kingdom.
Edinburgh Imaging Facility, Royal Infirmary of Edinburgh, EH16 4TJ Edinburgh, United Kingdom.

Iona Gerrish (I)

Centre for Clinical Brain Sciences, University of Edinburgh, EH16 4SB Edinburgh, United Kingdom.
Edinburgh Imaging Facility, Royal Infirmary of Edinburgh, EH16 4TJ Edinburgh, United Kingdom.

Yajun Cheng (Y)

Centre for Clinical Brain Sciences, University of Edinburgh, EH16 4SB Edinburgh, United Kingdom.
MRC UK Dementia Research Institute at the University of Edinburgh, EH16 4SB Edinburgh, United Kingdom.
Department of Neurology, West China Hospital of Sichuan University, 610041 Chengdu, China.

Xiaodi Liu (X)

Centre for Clinical Brain Sciences, University of Edinburgh, EH16 4SB Edinburgh, United Kingdom.
MRC UK Dementia Research Institute at the University of Edinburgh, EH16 4SB Edinburgh, United Kingdom.
Department of Medicine, LKS Faculty of Medicine, University of Hong Kong, Hong Kong, China.

Junfang Zhang (J)

Centre for Clinical Brain Sciences, University of Edinburgh, EH16 4SB Edinburgh, United Kingdom.
MRC UK Dementia Research Institute at the University of Edinburgh, EH16 4SB Edinburgh, United Kingdom.
Department of Neurology, Shanghai General Hospital, Shanghai Jiao Tong University School of medicine, 200080 Shanghai, China.

Agniete Kampaite (A)

Centre for Clinical Brain Sciences, University of Edinburgh, EH16 4SB Edinburgh, United Kingdom.

Eleni Sakka (E)

Centre for Clinical Brain Sciences, University of Edinburgh, EH16 4SB Edinburgh, United Kingdom.

Maria Valdés Hernández (M)

Centre for Clinical Brain Sciences, University of Edinburgh, EH16 4SB Edinburgh, United Kingdom.
MRC UK Dementia Research Institute at the University of Edinburgh, EH16 4SB Edinburgh, United Kingdom.

Stewart Wiseman (S)

Centre for Clinical Brain Sciences, University of Edinburgh, EH16 4SB Edinburgh, United Kingdom.
MRC UK Dementia Research Institute at the University of Edinburgh, EH16 4SB Edinburgh, United Kingdom.

Michael S Stringer (MS)

Centre for Clinical Brain Sciences, University of Edinburgh, EH16 4SB Edinburgh, United Kingdom.
MRC UK Dementia Research Institute at the University of Edinburgh, EH16 4SB Edinburgh, United Kingdom.

Michael J Thrippleton (MJ)

Centre for Clinical Brain Sciences, University of Edinburgh, EH16 4SB Edinburgh, United Kingdom.
MRC UK Dementia Research Institute at the University of Edinburgh, EH16 4SB Edinburgh, United Kingdom.
Edinburgh Imaging Facility, Royal Infirmary of Edinburgh, EH16 4TJ Edinburgh, United Kingdom.

Fergus N Doubal (FN)

Centre for Clinical Brain Sciences, University of Edinburgh, EH16 4SB Edinburgh, United Kingdom.
MRC UK Dementia Research Institute at the University of Edinburgh, EH16 4SB Edinburgh, United Kingdom.

Joanna M Wardlaw (JM)

Centre for Clinical Brain Sciences, University of Edinburgh, EH16 4SB Edinburgh, United Kingdom.
MRC UK Dementia Research Institute at the University of Edinburgh, EH16 4SB Edinburgh, United Kingdom.
Edinburgh Imaging Facility, Royal Infirmary of Edinburgh, EH16 4TJ Edinburgh, United Kingdom.

Classifications MeSH